Hengrui Medicine Makes First A-Share Buyback of 335,000 Shares for RMB 14.5 Million
On September 17, 2026, Hengrui Medicine repurchased 335,000 A shares through centralized bidding in its first such buyback, representing 0.005% of total share capital. The shares were bought at prices between RMB 43.10 and RMB 43.58 each, for a total of RMB 14.5036 million. The previously announced plan allows for a buyback of RMB 1 billion to RMB 2 billion using own funds for an employee stock ownership plan, running from August 19, 2026 to August 18, 2027.
On September 17, 2026, Hengrui Medicine repurchased 335,000 A shares through centralized bidding, marking its first such buyback. The shares represent 0.005% of the company's total share capital.
The repurchase was executed at a maximum price of RMB 43.58 per share and a minimum price of RMB 43.10 per share, with a total of RMB 14.5036 million paid.
Under the previously disclosed plan, Hengrui Medicine intends to use its own funds to repurchase shares through centralized bidding for an employee stock ownership plan. The total repurchase amount is set at no less than RMB 1 billion and no more than RMB 2 billion, with the repurchase period running from August 19, 2026 to August 18, 2027.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 30/100 and 70% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.